Combinatorial therapeutic approach for treatment of oral squamous cell carcinoma

References

• Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–316.
   PubMed Web of Science ®Google Scholar
• Lingen MW, Kalmar JR, Karrison T, et al. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008;44:10–22.
   PubMed Web of Science ®Google Scholar
• Mashberg A, Boffetta P, Winkelman R, et al. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer. 1993;72:1369–1375.
   PubMed Web of Science ®Google Scholar
• Gandini S, Botteri E, Iodice S, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122:155–164.
   PubMed Web of Science ®Google Scholar
• Petti S. Lifestyle Risk Factors for Oral Cancer. Oral Oncol. 2009;45:340–350.
   PubMed Web of Science ®Google Scholar
• Kantola S, Parikka M, Jokinen K, et al. Prognostic factors in tongue cancer – relative importance of demographic, clinical and histopathological factors. Br J Cancer. 2000;83:614–619.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Shah JP, Lydiatt W. Treatment of cancer of the head and neck. CA Cancer J Clin. 1995;45:352–368.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Mick R. Principles of pharmacokinetics and pharmacodynamics. In: Schilsky RL, Milano GA, Ratain MJ, editors. Principles of antineoplastic drug development and pharmacology. New York (NY): Marcel Dekker; 1996. p. 123–42.
   Google Scholar
• Lowenthal RM, Eaton K. Toxicity of chemotherapy. Hematol Oncol Clin North Am. 1996;10:967–990.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–265.
   PubMed Web of Science ®Google Scholar
• Links M, Brown R. Clinical relevance of the molecular mechanisms of resistance to anti‐cancer drugs. Expert Rev Mol Med. 1999;14:1–21.
   Google Scholar
• McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111:273–279.
   PubMed Web of Science ®Google Scholar
• Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 1994;48:794–847.
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Zhang HM, Sun XE, et al. Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice. Exp Ther Med. 2015;9:105–111.
   PubMed Web of Science ®Google Scholar
• Schilsky RL, Hohneker J, Ratain MJ, et al. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998;16:1450–1457.
   PubMed Web of Science ®Google Scholar
• Bram S, Froussard P, Guichard M, et al. Vitamin C preferential toxicity for malignant melanoma cells. Nature. 1980;284:629–631.
   PubMed Web of Science ®Google Scholar
• Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA. 2005;102:13604–13609.
   PubMed Web of Science ®Google Scholar
• Sestili P, Brandi G, Brambilla L, et al. Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically attainable concentrations of ascorbic acid: cell death prevention by extracellular catalase or catalase from cocultured erythrocytes or fibroblasts. J Pharmacol Exp Ther. 1996;277:1719–1725.
   PubMed Web of Science ®Google Scholar
• Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA. 2008;105:11105–11109.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:61–77.
   PubMed Web of Science ®Google Scholar
• Triplett MD. Enabling Solid lipid nanoparticle Drug Delivery Technology by Investigating improved production techniques. Athens (OH): The Ohio State University; 2004.
   Google Scholar
• Souto EB, Doktorovova S. Solid lipid nanoparticle formulations: pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol. 2009;464:105–129.
   PubMed Web of Science ®Google Scholar
• Seikmann B, Westesen K. Investigation on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Europen J Pharm. & Biopharm. 1996;43:104–109.
   Google Scholar
• Ahlin P, Kristl J, Kobar S. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersion. Acta Pharm. 1998;48:257–267.
   Google Scholar
• Bharadwaj R, Das PJ, Pal P, et al. Topical delivery of paclitaxel for treatment of skin cancer. Drug Dev Ind Pharm. 2016;42:1482–1494.
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Stainmesse S, et al. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Delivery Rev. 2006;58:1688–1713.
   PubMed Web of Science ®Google Scholar
• Souto EB, Wissing SA, Barbosa CM, et al. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278:71–77.
   PubMed Web of Science ®Google Scholar
• Kyo YC, Chung JF. Physicochemical properties of nevirapine loaded solid lipid nanoparticles and nano structured lipid carrier. Coll Sur B Biointer. 2011;83:299–306.
   PubMed Web of Science ®Google Scholar
• Patel MN, Lakkadwala S, Majrad MS, et al. Characterization and Evaluation of 5-Fluorouracil-Loaded Solid Lipid Nanoparticles Prepared via a Temperature-Modulated Solidification Technique. AAPS PharmSciTech. 2014;15:1498–1508.
   PubMed Web of Science ®Google Scholar
• Costa P, Sousa Lobo JM. Evaluation of mathematical model describing Drug release from estradiol transdermal systems. DDIP. 2003;27:89–97.
   Google Scholar
• Ekambaram P, Abdul Hasan Sathali A. Formulation and Evaluation of Solid Lipid Nanoparticles of Ramipril. J Young Pharma. 2011;3:216–220.
   PubMedGoogle Scholar
• Schoop RAL, Noteborn MHM, Baatenburg de Jong RJ. A mouse model for oral squamous cell carcinoma. J Mol Hist. 2009;40:177–181.
   PubMed Web of Science ®Google Scholar
• Schell A, Ley J, Wu N, et al. Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. Cancer Med. 2015;4:481–489.
   PubMed Web of Science ®Google Scholar
• Oertel K, Spiegel1 K, Schmalenberg H, et al. Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). BMC Cancer 2012;12:483.
   PubMed Web of Science ®Google Scholar
• Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. Jco. 2005;23:8636–8645.
   PubMed Web of Science ®Google Scholar
• Ma Y, Chapman J, Levine M, et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6:222–318.
   Web of Science ®Google Scholar
• Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharmac. 2008;363:132–138.
   PubMed Web of Science ®Google Scholar
• Shenoy VS, Vijay IK, Murthy RSR. Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles. J. Pharm. Pharmcol. 2005;57:411–422.
   PubMed Web of Science ®Google Scholar
• Swant KK, Petkar CK, Agrawal Y. Development, evaluation and clinical studies of acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 2010;401:93–102.
   PubMed Web of Science ®Google Scholar
• Hou D, Xie C, Huang K, et al. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003;24:1781–1785.
   PubMed Web of Science ®Google Scholar
• Shah R, Eldridge D, Palombo E, et al. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci. 2014;25:59–75.
   Google Scholar
• Fei H, Sanming L, Ran Y, et al. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Coll and Surf A. A Physicochem Eng Asp. 2008;315:210–216.
   Web of Science ®Google Scholar
• Patel K, Padhye S, Nagarsenker M. Duloxetine HCl lipid nanoparticles: preparation, characterization, and dosage form design. AAPS PharmSciTech. 2012;13:125–133.
   PubMed Web of Science ®Google Scholar
• Barratt G. Characterization of the colloidal drug carrier systems with zeta potential measurements. Pharma Tech Eur. 1999;11:25–32.
   Google Scholar
• Qi C, Chen Y, Jing Q-Z, et al. Preparation and characterization of catalase-loaded solid lipid nanoparticles protecting enzyme against proteolysis. Int J Mol Sci. 2011;12:4282–4293.
   PubMed Web of Science ®Google Scholar
• Schubert MA, Harms M, Muller RH, et al. Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur J Pharm Sci. 2006;27:226–236.
   PubMed Web of Science ®Google Scholar
• Casadei MA, Cerreto F, Cesa S, et al. Solid lipid nanoparticles incorporation in dextran hydrogels. Int J Pharm. 2006;325:140–146.
   PubMed Web of Science ®Google Scholar
• Hu QF, Jiang S, Du YZ, et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Coll and Surf B: Biointerfaces. 2005;45:167–173.
   PubMed Web of Science ®Google Scholar